Abstracts tagged "Graves’ disease and tocilizumab"

Abstract Number: 2268 • 2018 ACR/ARHP Annual Meeting
Anti-IL6-Receptor Tocilizumab in Graves’ Orbitopathy. Multicenter Study of 46 Patients
Belén Atienza-Mateo¹, José Luis Martín-Varillas¹, Vanesa Calvo-Río², Rosalía Demetrio-Pablo³, Diana Prieto Peña², Monica Calderón Goercke², Elia Valls-Pascual⁴, Beatriz Valls-Espinosa⁵, Olga Maiz-Alonso⁶, Ana Blanco⁷, Ignacio Torre-Salaberri⁸, Verónica Rodriguez-Mendez⁹, Angel Garcia-Aparicio¹⁰, Raúl Veroz González¹¹, Vega Jovaní¹², Diana Peiteado¹³, Margarita Sanchez Orgaz¹⁴, Santos Castañeda¹⁵, Eva Tomero¹⁶, Francisco J. Toyos Sáenz de Miera¹⁷, Valvanera Pinillos¹⁸, Elena Aurrecoechea¹⁹, Ángel Mora²⁰, Arantxa Conesa²¹, Manuel Fernández²², Nuria Avilés²³, J. Antonio Troyano²⁴, Miguel Angel González-Gay¹ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, ⁵Rheumatology, Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, ⁶Hospital Universitario Donostia. San Sebastian. Spain, Donostia, Spain, ⁷Ophtamology, Hospital Universitario Donostia. San Sebastian. Spain, San Sebastian, Spain, ⁸Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ⁹Ophthalmology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ¹⁰Rheumatology, Hospital de Toledo. Toledo. Spain, Toledo, Spain, ¹¹Rheumatology, Hospital de Mérida. Badajoz. Spain, Mérida, Spain, ¹²Rheumatology, Hospital General Universitario de Alicante. Spain, Alicante, Spain, ¹³Rheumatology, Rheumatology, La Paz University Hospital, Madrid, Spain, ¹⁴Ophthalmology, Hospital Universitario La Paz. Madrid. Spain, Madrid, Spain, ¹⁵Rheumatology, Hospital La Princesa. Madrid. Spain, Madrid, Spain, ¹⁶Rheumatology, Hospital de La Princesa. Madrid. Spain, Madrid, Spain, ¹⁷Hospital Virgen de La Macarena. Sevilla. Spain, Sevilla, Spain, ¹⁸Rheumatology, Hospital San Pedro. Logroño. La Rioja. Spain, Logroño, Spain, ¹⁹Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ²⁰Ophthalmology, Hospital de Sierrallana. Torrelavega. Cantabria. Spain, Torrelavega, Spain, ²¹Rheumatology, Hospital Clínico Universitario de Valencia. Spain, Valencia, Spain, ²²Hospital Universitario de Guadalajara. Spain, Guadalajara, Spain, ²³Rheumatology, Hospital Puerta del Mar. Cádiz. Spain, Cádiz, Spain, ²⁴Ophthalmology, Hospital Universitario Clínico San Carlos. Madrid. Spain, Madrid, Spain
Background/Purpose: To assess the efficacy of Tocilizumab (TCZ) in refractory thyroid associated orbitopathy (TAO) due to Grave’s disease.Methods: Multicenter study of 46 patients with TAO…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].